Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avid Amyvid Could Be Approved If Training Improves, Advisory Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The Peripheral and Central Nervous System Drugs Advisory Committee demands a second voting question to say the data support approval of the amyloid plaque diagnostic, but not until more consistent interpretation methods are developed.

You may also be interested in...



FDA Review Of GE’s Vizamyl Shows Caution In The Face Of Alzheimer’s Disease Unknowns

Regulators approved the PET imaging agent for estimating neuritic plaque density in the brain despite the apparent limited clinical utility of the class.

Amyvid Approval Just The Start Of A Critical Year For Alzheimer’s

One way or another, it is an important time in the Alzheimer’s disease space. Two potential disease altering therapies are set to divulge Phase III results that will answer important questions about the course of the illness, whether they are successful or not, and a promising cognition booster may get the Phase II readout it needs to head into a pivotal trial.

Medicare Coverage For Amyvid Complicated By PET Policy; Lilly Seeks Revision

Under CMS’ current policy for PET scans, new imaging agents approved by FDA would have to go through a national coverage analysis before Medicare will pay for them.

Related Content

Topics

UsernamePublicRestriction

Register

PS071715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel